Table 1.
Characteristics of included studies for vaccine therapy in advanced NSCLC patients after first-line therapy.
| Study | Country | Phase | Tumor stage | Sample, n | Male, n (%) | Age, y | First-line therapy | Intervention (sample, n) | Control (sample, n) | Extracted endpoint | Registration |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alfonso 201415 | Cuba | II/III | IIIB/IV | 176 | 118 (67%) | – | Chemo/Chemoradio | Racotumomab-alum (87) | Placebo (89) | OS, PFS, AEs | RPCEC00000009 |
| Besse 202316 | France | III | Advanced/Metastatic | 219 | 155 (70.8%) | 65 (41–86) | Chemo/ICB | OSE2101 (139) | SoC (80) | OS, AEs | NCT02654587 |
| Butts 201117 | Canada | IIb | IIIB/IV | 171 | 95 (55.6%) | 59 | Chemo/Chemoradio | BLP25 + BSC (88) | BSC (83) | OS | – |
| Butts 201418,a | Canada | III | III | 1239 | 846 (68.3%) | 61 (19–89) | Chemoradio | BLP25 (829) | Placebo (410) | OS, AEs | NCT00409188 |
| Giaccone 201519 | USA | III | IIIA/IIIB/IV | 532 | 307 (58%) | 61 ± 8.5 | Chemo/Chemoradio | Belagenpumatucel-L (270) | Placebo (262) | OS, PFS, AEs | NCT00676507 |
| Gridelli 202020 | Italy | II | IV | 190 | 132 (69.5%) | – | Chemo | Vx-001 (89) | Placebo (101) | OS | NCT01935154 |
| Katakami 201721 | Japan | II | III | 172 | 145 (84.3%) | 63 (33–86) | Chemoradio | BLP25 (114) | Placebo (58) | OS, PFS, AEs | – |
| Mitchell 201522,a | Australia | III | III | 1239 | 846 (68.3%) | 61 (19–89) | Chemoradio | BLP25 (829) | Placebo (410) | OS | NCT00409188 |
| Rodriguez 201623 | Cuba | III | IIIB/IV | 378 | – | – | Chemo | CIMAvax-EGF (246) | BSC (132) | OS, AEs | RPCEC00000161 |
| Takayama 201624 | Japan | II | IIIB/IV/Recurrent | 50 | 41 (82%) | – | Chemo/Radio | PPV vaccine + Docetaxel (26) | Placebo + Docetaxel (24) | OS, PFS, AEs | UMIN000003521 |
| Vinageras 200825 | Cuba | II | IIIB/IV | 74 | – | – | Chemo | CIMAvax-EGF (37) | BSC (37) | OS, AEs | – |
Chemo: Chemotherapy; Chemoradio: Chemoradiotherapy; Radio: Radiotherapy; ICB: Immune checkpoint blockers; BSC: Best supportive care; SoC: Standard of care; OS: Overall survival; PFS: Progression-free survival; AEs: Adverse events.
a
Studies reported from the same RCT, Mitchell 2015 updated the survival data.